获得性再生障碍性贫血与阵发性睡眠性血红蛋白尿症继发的骨髓增生异常综合征和白血病
获得性再生障碍性贫血(AA)和阵发性睡眠性血红蛋白尿症(PNH)是T细胞介导的自身免疫相关非恶性骨髓衰竭性疾病,与继发骨髓增生异常综合征(MDS)和急性髓系白血病(AML)风险增加相关。约15%至20%的AA患者和2%至6%的PNH患者在10年随访内发展为继发性MDS/AML。本文综述AA和PNH中体细胞突变的患病率与特征,探讨其预后意义和克隆选择机制,并讨论AA后和PNH后继发MDS/AML进展的现有数据,为存在克隆性造血(CH)的PNH和AA患者提供实用管理指导。
要点
- AA患者10年随访继发MDS/AML风险约15%至20%,PNH患者约2%至6%。
- AA中几乎普遍存在克隆性造血,多数PNH患者存在PIGA以外的体细胞突变。
- 疾病病程长、端粒磨损增加、不良预后突变及多突变与继发MDS/AML进展相关。
核心结论
- AA和PNH患者存在继发MDS/AML的长期风险,克隆性造血中的特定体细胞突变特征与恶性转化风险相关。
研究设计与样本
- 综述,检索范围未在原文中明确报告。
主要发现
- 约15%至20%的AA患者和2%至6%的PNH患者在10年随访内发展为继发性MDS/AML。
- AA患者中几乎普遍存在克隆性造血,多数PNH患者存在PIGA以外的体细胞突变。
- 与继发MDS/AML进展相关的因素包括疾病病程较长、端粒磨损增加、存在不良预后突变以及多突变,尤其当这些突变出现在疾病早期且等位基因负荷高时。
临床怎么用
- 原文为存在克隆性造血的PNH和AA患者的诊疗提供了实用指导,具体推荐内容未在摘要中报告。
局限性
- 决定个体患者恶性转化风险的因素仍不明确。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquired aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are pathogenically related nonmalignant bone marrow failure disorders linked to T-cell-mediated autoimmunity; they are associated with an increased risk of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Approximately 15% to 20% of AA patients and 2% to 6% of PNH patients go on to develop secondary MDS/AML by 10 years of follow-up. Factors determining an individual patient's risk of malignant transformation remain poorly defined. Recent studies identified nearly ubiquitous clonal hematopoiesis (CH) in AA patients. Similarly, CH with additional, non-PIGA, somatic alterations occurs in the majority of patients with PNH. Factors associated with progression to secondary MDS/AML include longer duration of disease, increased telomere attrition, presence of adverse prognostic mutations, and multiple mutations, particularly when occurring early in the disease course and at a high allelic burden. Here, we will review the prevalence and characteristics of somatic alterations in AA and PNH and will explore their prognostic significance and mechanisms of clonal selection. We will then discuss the available data on post-AA and post-PNH progression to secondary MDS/AML and provide practical guidance for approaching patients with PNH and AA who have CH.
引用
- Sun L, Babushok DV. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood. 2020. PMID: 32430502. doi:10.1182/blood.2019000940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。